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Tarah T Colaizy1*, Susan Carlson2, Audrey F Saftlas3 and Frank H Morriss Jr1Abstract
Background: To determine the effect of human milk, maternal and donor, on in-hospital growth of very low
birthweight (VLBW) infants. We performed a retrospective cohort study comparing in-hospital growth in VLBW
infants by proportion of human milk diet, including subgroup analysis by maternal or donor milk type. Primary
outcome was change in weight z-score from birth to hospital discharge.
Methods: Retrospective cohort study.
Results: 171 infants with median gestational age 27 weeks (IQR 25.4, 28.9) and median birthweight 899 g (IQR 724,
1064) were included. 97% of infants received human milk, 51% received > 75% of all enteral intake as human milk.
16% of infants were small-for-gestational age (SGA, < 10th percentile) at birth, and 34% of infants were SGA at
discharge. Infants fed >75% human milk had a greater negative change in weight z-score from birth to discharge
compared to infants receiving < 75% (−0.6 vs, -0.4, p = 0.03). Protein and caloric supplementation beyond standard
human milk fortifier was related to human milk intake (p = 0.04). Among infants receiving > 75% human milk, there
was no significant difference in change in weight z-score by milk type (donor −0.84, maternal −0.56, mixed −0.45,
p = 0.54). Infants receiving >75% donor milk had higher rates of SGA status at discharge than those fed maternal or
mixed milk (56% vs. 35% (maternal), 21% (mixed), p = 0.08).
Conclusions: VLBW infants can grow appropriately when fed predominantly fortified human milk. However, VLBW
infants fed >75% human milk are at greater risk of poor growth than those fed less human milk. This risk may be
highest in those fed predominantly donor human milk.Background
Maternal milk diets have been associated with advan-
tages for extremely low birthweight (ELBW) infants.
ELBW infants fed maternal milk have lower rates of nec-
rotizing enterocolitis (NEC) [1-3], the combined out-
come of NEC or death [4], late onset sepsis [2,5,6], and
have superior neurodevelopmental outcomes compared
with those fed preterm formulas [7,8].
However, maternal milk diets have also been asso-
ciated with inferior in-hospital growth when compared
with preterm formula. Studies performed prior to the
current practice of human milk fortification demon-
strated poorer growth in maternal–milk-fed infants* Correspondence: tarah-colaizy@uiowa.edu
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reproduction in any medium, provided the orcompared with those fed formula [9], although neurode-
velopmental advantages were associated with human
milk intake [7,10]. Results of subsequent studies of ma-
ternal milk intake and growth in VLBW infants during
the era of routine fortification have been mixed [1,2,11].
Slower in-hospital growth associated with a maternal
milk diet in ELBW infants remains a concern, because
poor in-hospital growth in ELBW infants is common
[12-14] and is associated with poor neurodevelopmental
outcomes at 18–22 mo [15].
The relationship between human milk intake and
growth becomes even less clear when donor human milk
diets for ELBW infants are considered. Pooled, pasteur-
ized donor human milk is a dietary intervention that is
increasing in usage in the very low birthweight (VLBW)
population in the US [16], but has not been well stud-
ied.. Early studies showed growth deficits withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ternal milk [17,18]. A later study comparing fortified
donor milk and preterm formula as supplements to for-
tified maternal milk also found slower growth associated
with donor milk [1]. Studies of the impact of donor
human milk diets on growth, particularly diets com-
posed predominantly of fortified donor human milk, are
needed to determine the safety and efficacy of this inter-
vention. Further studies of fortified maternal milk diets
are also needed to determine the growth effects in the
era of routine fortification. For the purposes of this
study, ‘maternal milk’ refers to human milk produced by
the mother of an infant. In contrast, ‘donor human milk’
refers to milk expressed by volunteer milk donors, pro-
cessed by the Mother’s Milk Bank of Iowa.
We undertook a retrospective cohort study to assess
in-hospital growth, as defined by change in weight z-
score for gestational age between birth and hospital dis-
charge, and incidence of growth failure defined as < 10th
percentile weight for corrected gestational age at hos-
pital discharge among infants weighing≤ 1250 g at birth
fed predominantly human milk diets.
Our objective was to study in-hospital growth of a
subset of VLBW infants treated in a center with exten-
sive human milk usage, including extensive use of donor
milk. We planned to study the effects of increasing pro-
portions of human milk fed during hospitalization, as
well as differential effects of predominantly maternal
milk vs. predominantly donor human milk diets. We
hypothesized that increasing fortified human milk intake
would be associated with slower, but adequate, growth,




We identified all infants born at University of Iowa Chil-
dren’s Hospital NICU or admitted by transport within
24 hours of birth with birthweights ≤ 1250 g between
January 1, 2003 and June 30, 2005 using a nutritional
database maintained by a neonatal dietician. Although
the formal definition of VLBW includes infants up to
1500 g at birth, our nutritional database includes only
infants weighing≤ 1250 g at birth. In this manuscript, all
references to our study population as VLBW should be
understood to refer only to the subset of VLBW infants
we studied. We included for analysis all of those who
were free of major chromosomal or structural congenital
anomalies and were discharged home or transferred to
another facility at ≥36 weeks’ gestational age. We
excluded those who died during hospitalization or were
transferred prior to 36 weeks to focus on growth in
infants from birth through typical hospital discharge
range. Clinical and demographic variables were collectedretrospectively from the subjects’ medical records. The
Mother’s Milk Bank of Iowa, a Human Milk Banking As-
sociation of North America (HMBNA) member bank,
dispensed its first milk to the UICH NICU in May 2003.
All donor human milk fed to infants in this study was
obtained from the MMBI. Milk donors were unpaid
volunteers, most of whom had delivered term infants.
Milk from 3–10 donors was pooled and pasteurized by
the Holder method in batches of 4.3 L in accordance
with HMBANA standards. The MMBI does accept
donations of milk from women who deliver preterm
infants but does not process this milk separately or label
milk as ‘preterm’ or ‘mature’. This study was approved
by the University of Iowa IRB.
Clinical variables
Intraventricular hemorrhage (IVH) was defined by high-
est grade recorded, retinopathy of prematurity (ROP)
was defined by highest stage reported, necrotizing en-
terocolitis (NEC) was defined by Bell’s stage II or higher,
late onset sepsis (LOS) was defined by a positive blood
culture after 3 days of age accompanied by IV antibiotic
therapy, and patent ductus arteriosus (PDA) was defined
by presence of hemodynamically significant patent
ductus on echocardiogram that was treated with indo-
methacin or surgical ligation. We also collected dis-
charge home on supplemental oxygen.
Nutritional intake and growth variables
Human milk intake data were collected from nursing
flowsheets by recording separately daily intake of mater-
nal and donor milk. Human milk intake was categorized
by percent of total enteral intake during hospitalization
(<25% of diet, 25-50% of diet, 51-75% of diet, and >75%
of diet), combining donor and maternal milk intakes. All
enteral intake that was not human milk was various in-
fant formula preparations. The subgroup of infants re-
ceiving >75% of enteral intake as human milk were
further subdivided for analysis by milk type: >75% donor
milk, >75% maternal milk, and a >75% human milk diet
of mixed donor and maternal milk. Postmenstrual age-
specific z-scores, based on the Fenton growth chart,
were calculated for birth weight, discharge weight, and
discharge occipito-frontal circumference (OFC) [19].
SGA status at discharge was defined as < 10th percentile
for postmenstrual age according to the Fenton growth
chart. We chose to use z-scores rather than weight mea-
surements because this allows us to use hospital dis-
charge as the outcome time point, which varies from
subject to subject. It also provides standardization to a
recognized scale, the widely-used and validated Fenton
growth chart. If maintenance of the in-utero growth rate
for VLBW infants is achieved, an infant born with a
weight z-score of 0 (50th percentile for postmenstrual
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age at discharge. Negative change in weight z-score from
birth to discharge represents growth less than the pre-
dicted growth rate, whereas positive change represents a
growth rate greater than the predicted growth rate.
Study outcomes
The primary outcome of the study was change in weight
z-score for postmenstrual age from birth through dis-
charge, stratified by quantity of human milk received.
Secondary outcomes included weight z-score for post-
menstrual age at discharge and discharge SGA status by
human milk intake. Subgroup analyses of change in
weight z-score, discharge weight z-score, discharge OFC
z-score, and discharge SGA status were performed on
the infants receiving >75% human milk. Protein and cal-
orie supplementation beyond 24 kcal/oz (2–2.3 g pro-
tein/dl) was also compared by human milk intake across
the whole study population, and also within the >75%
human milk subgroup.
Nutritional management
Nutritional management of this subgroup of VLBW
infants at UICH under daily guidance by the neonatal
dietician was uniform during this study period, except
for the introduction of donor human milk, which oc-
curred 6 months into the 30 month study period. All
infants received IV glucose within an hour of birth. Par-
enteral nutrition (TPN) with provision of 2–3 g/kg/day
of protein and 1–2 g/kg/day of fat as Intralipid 20%
(Baxter) was started on day of life 0 or 1. Parenteral pro-
tein administration goal was 3 g/kg/d, and lipid dose
goal was 2 g/kg/d. Parenteral amino acid intakes were
maintained at 3 g/kg/d until parenteral volume fell
below 60 ml/kg/d and then maintained at 5 g/dl until
TPN was discontinued. Glucose infusion rates were
titrated to maintain blood glucose measurements less
than 160 mg/dl, with insulin used only rarely for severe
refractory hyperglycemia. Enteral feedings were started
between day of life 0 and 2, with maternal colostrum,
unfortified pooled pasteurized donor human milk, or
preterm formula (24 kcal/oz) per parents’ and treating
team’s preference. Maternal milk was typically stored
frozen and thawed prior to feeding, although fresh milk
was used when available. Feeding volume was ≤5 ml/kg/
day on the first day, and increased by no more than
20 ml/kg/day. Minimal target enteral caloric intake was
120 kcal/kg/day, minimal target enteral protein intake
was 3.6 g/kg/day, with an optimal target of 4 g/kg/day.
Maternal and donor human milk were fortified to ~2-
2.3 g/dl protein (24 kcal/oz) with powdered bovine
human milk fortifier according to manufacturer direc-
tions (4 packets/100 ml) when infants were tolerating at
least 25 ml of milk intake per day, with fortificationtypically occurring when volumes were between 25 and
40 ml per day. We chose to fortify at 25 ml per day at
the earliest to avoid wastage of maternal milk, as forti-
fied milk can be kept refrigerated for up to 24 hours be-
fore discarding, and one packet of fortifier is mixed in
25 ml of milk. To achieve target protein intake, maternal
and donor human milk were fortified further to 2.4-
2.65 g/dl protein (27 kcal/oz) in the majority of infants
by addition of more human milk fortifier powder (6
packets/100 ml). To achieve target protein intake in
infants requiring fluid restriction, milk was fortified by
adding 30 ml term formula concentrate and 6 packets
HMF/100 ml to provide 2.5-2.7 g/dl protein (30 kcal/
oz). Parenteral nutrition was discontinued and central
venous lines removed when infants were tolerating
100 ml/kg/day of enteral intake.
Statistical analysis
Demographic characteristics and clinical outcomes were
compared among milk intake groups, using Chi-squared
or Fisher’s exact tests for categorical variables, and one-
way ANOVA for continuous variables across all study
groups. These analyses were repeated for the subgroup
of infants receiving > 75% of all in-hospital enteral intake
as human milk stratified by human milk type. Growth
and nutritional variables were compared in univariate
fashion among human milk intake groups and full milk
diet subgroups using repeated-measures ANOVA or
ANOVA as appropriate. SAS 9.2 (SAS Institute, Cary,
NC, USA) was used for all analyses.
Results
Between January 1, 2003 and June 30, 2005, 224 infants
with birthweights less than 1251 g were admitted to UICH
NICU by birth or transfer at less than 24 hours’ age. Eight-
een infants died before discharge, 32 were transferred to
other facilities before 36 weeks’ postmenstrual age, and 3
were excluded for congenital anomalies, leaving 171 sub-
jects included in the analyses. Demographic and clinical
characteristics for the all subjects are shown in Table 1.
Median postmenstrual-age-specific weight z-score was ap-
propriate for gestational age at birth (−0.4; i.e. 35th per-
centile), and at discharge (−0.94, i.e. 17th percentile), but
significantly decreased from birth to discharge ( −0.51
change in z-score, p < 0.0001). Infants receiving< 25%
human milk (17 days) and those receiving >75% human
milk (20 days) had shorter durations of central line and
TPN use than those receiving 25-50% human milk
(26 days) and those receiving 50-75% human milk
(22 days)(p = 0.008, Table 1). 97% of infants received at
least some human milk during hospitalization. Only 5 of
171 infants received no human milk and were included in
the <25% group. 16% of infants were SGA, (<10th percent-
ile for gestational age) at birth, and 34% of infants were
Table 1 Characteristics for all subjects and by human milk intake
Group by proportion of enteral intake as human milk
All subjects <25% 25-50% 50-75% >75% p value*
n = 171 n= 17 n=30 n=36 n=88
Male sex n (%) 85 (49) 6 (35) 12 (40) 21 (58) 45 (51) 0.52
Gestational age, weeks, median (IQR) 27 28.43 26.86 26.64 27 0.63
(25.4, 28.9) (25.4, 29.6) (25.4, 29.0) (25.7, 28.5) (25.6, 28.8)
Birthweight, g, median (IQR) 889 1083 861 848 880 0.31
(724, 1064) (778, 1184) (736, 1091) (717, 1011) (719, 1052)
Birthweight z-score, median (IQR) −0.40 −0.32 −0.19 −0.48 −0.45 0.98
(−0.99, 0.29) (−0.52, 0.05) (−0.89, 0.12) (−1.15, 0.29) (−0.93, 0.33)
SGA at birth n (%) 27 (16) 3 (18) 4 (13) 7 (19) 13 (15) 0.89
Maternal antenatal steroids n (%) n= 163 132 (81) 14 (88) 22 (79) 30 (88) 65 (78) 0.55
Postnatal dexamethasone n (%) 53 (31) 5 (29) 10 (30) 12 (34) 25 (28) 0.90
Age at first enteral
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Central line days, median (IQR) 22 17 26 22 20 0.008
(13, 33) (9, 27) (15, 37) (14, 34) (13, 31)
NEC n (%) 3 (2) 0 (0) 0 (0) 1 (3) 2 (2) 1
ROP n (%) 63 (38) 7 (47) 14 (50) 11 (33) 27 (33) 0.32
PDA n (%) 85 (49) 5 (29) 16 (53) 17 (49) 45 (51) 0.40
Sepsis n (%) 26 (15) 3 (18) 6 (20) 9 (25) 8 (9) 0.09
IVH n (%) 31 (18) 1 (6) 4 (13) 2 (6) 23 (27) 0.02
Oxygen at discharge n (%) 116 (67) 11 (65) 20 (67) 23 (64) 60 (68) 0.97
Postmenstrual age at























* Chi-squared, Fisher’s exact test, or ANOVA across all groups.
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ity remained so at discharge (22/27, 81%). Among infants
AGA at birth, 21% were SGA at discharge (36/144), with
79% (108/144) remaining AGA.Growth by percent of intake as human milk
There were no significant differences in gestational age,
birth weight, birth weight z-score, or gender among
groups. Neonatal morbidities were also similar, with no
significant difference in incidence of ROP, PDA, NEC, or
oxygen at discharge among groups (Table 2). Protein
supplementation varied among human milk intake
groups. The majority of infants in all groups received
protein supplementation beyond the standard human
milk fortifier at 2–2.3 g/dl (65-85% of infants), and
infants receiving larger proportions of human milk were
more likely to receive protein supplementation beyond
2–2.3 g/dl than those receiving less (p = 0.04, Table 2).Change in weight z-score from birth to discharge and
discharge weight z-scores did not vary significantly by
human milk intake (Table 2), but all groups experienced
significant decreases in weight z-score from birth to dis-
charge (p< 0.0001). The decrease in weight z-score was
largest for the >75% milk group (−0.6), compared with the
other groups (−0.1 to −0.32, p = 0.17) (Figure 1A.). Rates
of SGA at discharge did not vary by human milk intake
(Table 2). When the > 75% milk group was compared with
the rest of the study population as a single group receiv-
ing< 75% human milk, infants fed > 75% human milk
experienced a significantly larger decrease in weight z-
score between birth and discharge (−0.59 vs. -0.36, p 0.03).
Growth by human milk type
51% of the study population (88/171) received > 75% of
all enteral intake during hospitalization as human milk:
maternal, donor, or a mixture of both (Table 2). 31 of
these 88 infants received > 95% of all enteral intake as
Table 2 Growth outcomes and human milk fortification for all subjects and by human milk intake
Group by proportion of enteral intake as human milk p value
All Subjects <25% 25-50% 50-75% >75% All groups >75% vs. <75%
Discharge










(2335, 3035) 0.008* 0.0006
Discharge












SGA at discharge n (%) 58 (34) 7 (41) 8 (27) 9 (25) 34 (39) 0.36* 0.18
Protein fortification, highest level
n (%)
2.0-2.3 g/dl 34 (20) 6 (35) 8 (27) 6 (17) 14 (16) 0.04† 0.18
2.4-2.65 g/dl 84 (49) 6 (35) 14 (46) 16 (44) 48 (55)
2.5-2.7 g/dl 53 (31) 5 (29) 8 (27) 14 (39) 26 (30)
Change in weight z-score,












*ANOVA or Chi square across all groups.
†Chi square across all fortification levels and all human milk intake groups.
{ p< 0.0001 – t-test of change in weight z score = 0, infants experienced significant negative change in weight z-score from birth to discharge.
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received between 75 and 80%. Of the 88 infants who
received >75% of intake as human milk, 23 received
>75% donor milk, 51 received >75% maternal milk, and
the remaining 14 received a combination of both types of
milk with neither comprising 75% of the diet (Table 3).
17 infants in the donor milk group received maternal
milk as well, and 16 infants in the maternal milk group
received donor milk. There were no significant differ-
ences in birthweight, birthweight z score, gestational age,
or sex among human milk type subgroups. There were
no statistically significant differences in the prevalence of
neonatal morbidities that may influence growth, includ-
ing NEC, PDA, sepsis, ROP, IVH, oxygen at discharge,
nor in the use of postnatal dexamethasone to treat BPD
between milk type subgroups (data not shown).
The majority of all infants receiving >75% of enteral
intake as human milk received protein and calorie sup-
plementation beyond standard 24 kcal/oz (84-93%,
Table 3), and the pattern of protein and calorie supple-
mentation did not vary significantly by milk type.
Change in weight z-score from birth to discharge, dis-
charge weight z-score, and discharge OFC z-score did
not differ significantly by human milk type, both when all
three milk type groups were compared, and when donor
milk and maternal milk were directly compared (Table 3)
(Figure 1B). There was a trend toward higher rates of
SGA at discharge in donor milk fed infants (56%) than in
those fed maternal milk (35%) or mixed donor and ma-
ternal milk (21%)(p = 0.08, Table 3).
Discussion
Our population of VLBW infants fed predominantly
human milk experienced low rates of SGA at discharge,and average loss of one-half of a standard deviation in
weight for gestational age between birth and discharge.
Although increasing proportions of enteral intake as
human milk were not associated with increasing detri-
ment in weight z-score, infants fed >75% human milk
experienced significantly larger decrease in weight z-
score from birth to discharge when compared with
infants fed < 75% (p = 0.03). In addition, among infants
fed > 75% human milk, infants fed predominantly donor
human milk demonstrated higher rates of SGA at dis-
charge than those fed maternal milk or mixed donor and
maternal milk (p = 0.08).
The study infants grew well overall by the definition of
being AGA at birth (z-score −0.4, i.e.35th percentile),
and appropriate for postmenstrual age at discharge (z-
score −0.94, i.e. 17th percentile). In-hospital growth fail-
ure, as defined by SGA status at 36 weeks’ postmenstr-
ual age, has previously been described as a problem in
the VLBW population. Dusick and colleagues described
a population of 1433 infants from the NICHD Neonatal
Research Network (NRN) born between 2000 and 2001.
They determined that while only 16% of VLBW infants
were SGA at birth, 89% met this definition at 36 weeks
postmenstrual age [14]. Those outcomes represented an
apparent improvement in rates of growth failure among
VLBW infants in the NRN, as 97% of 4438 infants ad-
mitted to NRN centers between 1995 and 1996 were
SGA at postmenstrual age at 36 weeks [20]. In contrast,
34% of our subjects were SGA at discharge, which oc-
curred at a median postmenstrual age of 38.7 weeks, and
only 21% of infants who were AGA at birth had become
SGA by the time of discharge.
As reported by other investigators, predominantly
human milk diets in our population (>75%) resulted in
Figure 1 Change in weight z-score from birth to discharge according to the Fenton growth chart, by proportion of enteral diet as
human milk. A. Change in weight z-score by proportion of enteral intake as human milk, all subjects. B. Change in weight z-score by type of
human milk diet among infants receiving >75% of enteral intake as human milk. MM = maternal milk; DM = donor human milk; Mixed MM/DM
= diet contained >75% human milk, a mixture of both maternal and donor milk, neither of which comprised >75% of the diet.
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significantly larger decrease in weight z-score between
birth and discharge, than diets containing <75% human
milk, although no dose–response effect was noted be-
tween increasing proportion of human milk and growth.
Schanler and colleagues studied a similar population of
VLBW infants, comparing those fed an average of 84%
of the in-hospital diet as fortified human milk to those
fed solely preterm formula. They found that human-
milk-fed infants experienced slower weight gain, and
were 500 g lighter at discharge than their formula-fed
peers [2]. Using the Fenton chart to calculate z-scores
for Schanler’s study results in a weight z-score change of
−1.86 for the human milk group compared with a weight
z-score change of −1.34 for the formula group. O’Con-
nor and colleagues also found a negative dose–response
relationship between human milk intake and in-hospital
growth as measured by weight at term-adjusted age.
Among their population of larger VLBW infants (mean
GA 30 wks, 1275 g birthweight), infants fed > 80% forti-
fied human milk weighed 500 g less at term-adjusted agethan those fed solely formula [11]. Negative change in
weight z-score calculated using the Fenton chart from
birth to term in their study was also related to human
milk, with the largest decline seen among those fed the
most human milk (−1.62), and the least decline seen
with exclusive formula feeding (−0.64).
A predominantly donor milk diet was associated with
higher rates of growth failure as defined by discharge
weight < 10th percentile for postmenstrual age (SGA) in
our population, compared with predominantly maternal
milk and mixed human milk diets (p = 0.08). Infants fed
predominantly mixed human milk diets had the lowest
rates of SGA of all infants in the subgroup of infants fed
>75% human milk. Although all infants included in the
>75% human milk subgroup analysis received >75%
human milk, intake varied systematically. Infants in the
mixed diet group received 75-80% human milk, while
infants in the maternal and donor groups received 85-
100% human milk. The rate of SGA in the mixed group
(21%) is therefore closer to the rate of SGA for the 50-
75% human milk group (25%) than that of the >75%
Table 3 Growth outcomes and human milk fortification, >75% human milk diet group
Subgroup by type of human milk p value all
3 groups
p value >75% DM vs.
>75% MM
>75% DM n=23 >75% MM n=51 Mixed MM/DM n=14
Birthweight, g, median (IQR) 868 993 769
(643, 997) (767, 1100) (694, 822) 0.07 0.22
Birthweight z-score, median, (IQR) −0.41 −0.49 −0.14
(−0.99, -0.03) (−0.90, 0.48) (−0.66, 0.35) 0.74 0.66
Discharge weight, g median (IQR) 2330 2710 2875
(2070, 2720) (2480, 3050) (2500, 3200) 0.07 0.09
Discharge weight z-score median (IQR) −1.36 −1.04 −0.68
(−1.83, -0.48) (−1.43, -0.26) (−1.2, -0.17) 0.24 0.16
SGA at discharge n (%) 13 (56) 18 (35) 3 (21) 0.08 0.13
Protein fortification,
highest level used n (%)
2.0-2.3 g/dl 3 (13) 10 (20) 1 (7)
2.4-2.65 g/dl 13 (57) 27 (53) 8 (57)
2.5-2.7 g/dl 7 (30) 14 (27) 5 (36) 0.82 1
Discharge head circumference, cm 32 33.5 33.25 0.23 0.10
(n = 56) median (IQR) (31.5, 33.5) (32.5, 34.75) (32.25, 34.25)
Discharge head −0.7 −0.4 −0.9
circumference z-score median (IQR) (−1.4, -0.2) (−1, 0.4) (−1.15, -0.25) 0.11 0.10
Change in weight z-score,
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and 3). Sullivan and colleagues also reported growth out-
comes in a population of VLBW infants fed >70% mater-
nal milk, some of whom received a formula supplement
as the remainder of the diet, and some of whom received
donor human milk [3]. Infants receiving donor human
milk in this trial also received human milk human milk
fortifier, in contrast to the bovine milk human milk forti-
fiers used both in all other studies discussed and in our
subjects. Infants fed the donor milk supplement showed
a trend toward slower weight gain than those fed a for-
mula supplement (p = 0.13).
A possible explanation for slower growth rates among
infants fed fortified human milk, in general, and donor
milk, specifically, is the inadequate protein content of
standard fortified human milk for the needs of VLBW
infants. Growth of preterm infants is linearly related to
protein intake [21]. Enteral protein requirements to
achieve in-utero growth rates in VLBW infants range be-
tween 4 g/kg/day for the <1000 g infants and 3.6 g/kg/
day for 1200–1500 g infants [22]. Despite the higher
protein content of milk produced by mothers delivering
preterm [23,24] and routine use of human milk fortifiers,
VLBW infants fed human milk experience a protein def-
icit during the initial months of life. This deficit has been
estimated by Arsanoglu et al, who compared assumedprotein intake for VLBW infants to actual intake, to be
0.5 to 0.8 g/kg/day [25].
Inadequate protein intake is even more pronounced
when donor milk is considered. Most donor human milk
is obtained from donors who delivered term infants and
have been lactating for several months, and thus does
not contain the higher preterm protein levels. There is
evidence that donor milk contains even lower protein
content than standard mature human milk, possibly due
to processing and handling. Wojcik et al studied 415
samples of unpooled donor milk from 273 donors and
found that the median protein content was 1 g/dl and
that 30% of samples contained < 1 g/dl [26]. Mean pro-
tein content in 39 samples from donors to the Mother’s
Milk Bank of Ohio was 0.9 mg/dl [27]. Using standard
powdered bovine HMF with donor milk thus results in a
diet severely deficient in protein, i.e. 2.8-3 g/kg/day, in-
creasing the risk for growth failure.
Growth can be optimized with human milk in general,
and donor milk specifically, if this relative protein defi-
ciency is recognized and diets are modified to provide ad-
equate protein intake. Protein intake can be optimized in
either individualized or group methods [28,29]. The ap-
proach now taken in our unit is to increase protein intake
for all infants, with target intake of 3.6-4 g/kg/day, without
attempting to individualize intake. Our findings of lower
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tributable to higher protein intake in our predominantly
human-milk-fed subgroup of VLBW infants. However, as
multi-component fortifiers were used to achieve target
protein intakes (bovine human milk fortifiers and term
formula concentrate) in our population, overall caloric
content of the milk was also increased in addition to pro-
tein. Some of the growth results obtained with our ap-
proach may be due simply to higher caloric density of the
milk, however, protein intake has been found to be
strongly linked to growth in VLBW infants [21].
This study’s strengths include the prospectively col-
lected growth and nutritional information and the use of
z-scores, which allow for comparison of growth out-
comes to a recognized standard. Our study also includes
a significant number of VLBW infants fed donor human
milk, and allows us to compare predominantly donor
milk to predominantly maternal milk diets.
Our study’s weaknesses include the limited sample size
and observational nature. Using an observational study
design did not allow us to control enteral intake or com-
pare different protein intakes in a randomized fashion.
Use of donor milk or specific protein fortification
schemes may have been systematically associated with
other infant factors that impacted growth, creating re-
sidual confounding. In addition, we collected weight data
only at birth and discharge, and were not able to assess
the timing of the lowest weight z-score experienced by
the infants, or how the trajectory of weight growth may
have changed from day to day or week to week during
hospitalization. We do not assume that the weight z-
score at discharge represents the lowest weight z-score,
we only report the change between birth and discharge.
We were also unable to assess the effects of donor or
maternal human milk on linear growth in our popula-
tion, as standardized length data were not obtained.
Ramel and colleagues have recently demonstrated that
poor in-hospital linear growth is associated with poor
cognitive outcomes in former VLBW infants at age 2,
and that length z-scores for gestational age were lower
than weight z-scores in their population [30]. Future
studies should include standardized length measure-
ments. Another limitation of our study is that we did
not measure caloric intake or protein intake directly,
and therefore we are unable to report the intakes needed
to achieve the growth results we demonstrated.
Conclusions
Human milk offers many benefits for VLBW infants,
and should be the default diet for all such infants. We
demonstrate that in-hospital growth of VLBW infants
can be adequate with predominant human milk diets,
both maternal and donor derived. Our population
experienced low rates of SGA at discharge, and averageloss of one-half of a standard deviation in weight for ges-
tational age between birth and discharge. Donor human
milk diets may be associated with more growth chal-
lenges than maternal milk diets. Special attention to pro-
tein and calorie fortification is necessary to provide the
benefits of a human milk diet without sacrificing growth.
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